The DOI matches its Crossref record; 60 of the 61 references it cites were found in a registry or an index.
Future therapies for obesity
Open accessAbstract
Obesity is a chronic disease associated with increased morbidity and mortality. Bariatric surgery can lead to sustained long-term weight loss (WL) and improvement in multiple obesity-related complications, but it is not scalable at the population level. Over the past few years, gut hormone-based pharmacotherapies for obesity and type 2 diabetes mellitus (T2DM) have rapidly evolved, and combinations of glucagon-like peptide 1 (GLP1) with other gut hormones (glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) as dual or triple agonists are under investigation to enhance and complement the effects of GLP1 on WL and obesity-related complications. Tirzepatide, a dual agonist of GLP1 and GIP receptors, marks a new era in obesity pharmacotherapy in which a combination of gut hormones could approach the WL achieved with bariatric surgery. In this review, we discuss emerging obesity treatments with a focus on gut hormone combinations and the concept of a multimodal approach for obesity management.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, there is still a significant difference between the WL that can be achieved with bariatric surgery and the currently approved obesity pharmacotherapies and there is heterogeneity in treatment responses with GLP-1 RA (for example people with T2D may achieve less WL compared to those without diabetes in clinical trials, despite similar lifestyle interventions) [13, 14].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As obesity is a complex, chronic and progressive disease, it requires also an individualised and adaptive over time approach [14, 102].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As older molecules will lose patent over next years and a plethora of new molecules will come to the market, it is likely that competition will have a positive impact on the obesity medication prices [14].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Similar to other chronic diseases, if the treatment for the disease of obesity is stopped, weight regain will likely occur and the health benefits will be diminished [14].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [14]
In the citing paper
“There was no increased risk of hypoglycemia in people with T2D, except when tirzepatide was combined with sulfonylurea or insulin [54].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
The biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
Bray, G. A., Kim, K. K., Wilding, J. P. H., & on behalf of the World Obesity Federation (2017) · Obesity Reviews · doi:10.1111/obr.12551 · Cited by 1,612
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
Liraglutide and renal outcomes in type 2 diabetes
Mann, J. F. E., Ørsted, D. D., Brown-Frandsen, K., Marso, S. P., Poulter, N. R., Rasmussen, S., Tornøe, K., Zinman, B., & Buse, J. B. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1616011 · Cited by 1,253
Wilding, J. P. H., Batterham, R. L., Davies, M., Van Gaal, L. F., Kandler, K., Konakli, K., Lingvay, I., McGowan, B. M., Oral, T. K., Rosenstock, J., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14725 · Cited by 1,128
Research works printed but not linked: 2
- 2022, Diabetologia, 65, 1
- 53 Amgen,. Amgen presents new AMG 133 phase 1 clinical data at WCIRDC 2022. www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022 [Accessed 25 May 2023].
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Similar to other chronic diseases, if the treatment for the disease of obesity is stopped, weight regain will likely occur and the health bene fi ts will be diminished [14].”
InfluentialSelf-citationGkrinia, E. M. M., & Belančić, A. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050357 · Cited by 176
“Retatrutide’s triple action on GLP-1, GIP, and glucagon receptors shows promise in phase II trials, with early data indicating 17–22% weight reduction through combined appetite suppression and enhanced energy expenditure [61,62].”
InfluentialTirzepatide for overweight and obesity management
Hamza, M., Papamargaritis, D., & Davies, M. J. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2436595 · Cited by 73
“Based on these findings, maridebart cafraglutide, a monoclonal antibody that antagonizes the GIP receptor and is conjugated to two modified GLP-1 peptides, which activate the GLP-1 receptor, is also in early-phase clinical trials as obesity treatment [17,29,30].”
Self-citationNew drugs for the treatment of obesity: do we need approaches to preserve muscle mass?
Ryan, D. H. (2025) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-025-09967-4 · Cited by 34
“[37] This term refers to using the GLP-1 R target to carry weight loss and disease modifying benefits but to add, either in single molecule or in multiple dosing, the ability to target additional NuSH receptors to gain additional benefits.”
Gogineni, P., Melson, E., Papamargaritis, D., & Davies, M. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2356254 · Cited by 32
“There was no increased risk of hypoglycemia in people with T2D, except when tirzepatide was combined with sulfonylurea or insulin [54].”
BackgroundSelf-citation
Metadata
- Authors
- Melson, E., Miras, A. D., & Papamargaritis, D.
- Affiliations
- University of Leicester (GB)
- University of Ulster (GB)
- Venue
- Clinical Medicine
- Publisher
- Elsevier BV
- Published
- 2023-07
- Volume
- 23
- Issue
- 4
- Pages
- 337-346
- ISSN
- 1470-2118 (ISSN-L)
- PMC
- PMC10541050
- OpenAlex
- W4385431101
- Semantic Scholar
- 6ffcced65a686ecf036b1802ae7e3078366b6cfc
- Cited by
- 46
- References
- 61
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 13 · 2023: 3
- FWCI
- 7.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 285 d)
- Locations
- Clinical Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Ulster University Research Portal (Ulster University) (publishedVersion, other-oa)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institute for Health and Care Research (ACF-2022-11-007)
- NIHR Leicester Biomedical Research Centre
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- obesity, obesity pharmacotherapy, bariatric surgery, gastrointestinal hormones, GLP-1 receptor agonists, GIP receptor agonist, tirzepatide, weight loss, type 2 diabetes, glucagon, amylin
- MeSH terms
- Diabetes Mellitus, Type 2, Gastrointestinal Hormones, Humans, Obesity, Weight Loss, Bariatric Surgery, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Future therapies for obesity. https://app.cochat.ai/papers/10.7861/clinmed.2023-0144
- The paper
- Melson, E., Miras, A. D., & Papamargaritis, D. (2023). Future therapies for obesity. Clinical Medicine. https://doi.org/10.7861/clinmed.2023-0144
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.